Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Exclusion Criteria

• •Previous high-dose therapy and blood stem cell transplantation except for melphalan 140 mg/m2 or 200 mg/m2 in patients with multiple myeloma who did not participate in the cytocapacity test previously (according to amendment 2, see Section 9.8.1).
• •Known intolerance to lenograstim
• •Out-patient therapy following high-dose therapy and blood stem cell transplantation
• •Myocardial infarction \< 6 months prior to inclusion into the study
• •Cardiac arrhythmias Lown IV b
• •Clinically manifest cardiac insufficiency (\> NYHA II)
• •Renal insufficiency with serum creatinine \> 2 mg%
• •Hepatic diseases with elevated levels of transaminases and bilirubin greater than 3-fold above normal
• •Severe infections (HIV, Hepatitis B/C)
• •Severe psychiatric diseases
• •Non-curative treatment of other malignoma within the past 5 years
• •Pregnant women or women breast-feeding